First patients receive experimental cancer drug in new trial
NCT ID NCT06384352
Summary
This is the first study in people to test a new cancer drug called YL211. It aims to find a safe dose and see how the body processes the drug in patients with advanced solid tumors that have not responded to standard treatments. The main goals are to check for side effects and see if the drug shows any early signs of helping to control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China-Japan Friendship Hospital
RECRUITINGBeijing, Beijing Municipality, 100029, China
Contact
-
Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley
ACTIVE_NOT_RECRUITINGLas Vegas, Nevada, 89169, United States
-
Florida Cancer Specialists & Research Institute (FCS) - Sarasota Cattlemen Office
RECRUITINGSarasota, Florida, 34232-6422, United States
Contact Email: •••••@•••••
Contact
-
Gosford Hospital
ACTIVE_NOT_RECRUITINGGosford, New South Wales, 2250, Australia
-
Monash Health
RECRUITINGMelbourne, Australia
Contact Email: •••••@•••••
Contact
-
NEXT Oncology - Dallas
RECRUITINGIrving, Texas, 75039, United States
Contact Email: •••••@•••••
Contact
-
NEXT Oncology - Houston
RECRUITINGHouston, Texas, 77055, United States
Contact
-
NEXT San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Email: •••••@•••••
-
One Clinical Research - Nedlands
NOT_YET_RECRUITINGNedlands, Western Australia, 6009, Australia
Contact
-
Princess Margaret Hospital
RECRUITINGToronto, Toronto, Canada
Contact Email: •••••@•••••
Contact
-
Sarah Cannon Research Institute (SCRI) at HealthONE
RECRUITINGDenver, Colorado, 80218-1238, United States
Contact Email: •••••@•••••
Contact
-
Sarah Cannon Research Institute at Florida Cancer Specialists
RECRUITINGOrlando, Florida, 32827, United States
Contact
Contact Email: •••••@•••••
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, China
Contact Email: •••••@•••••
Contact
Contact
-
The First Affiliated Hospital - Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310003, China
Contact
-
The Ottawa Hospital - General Campus
NOT_YET_RECRUITINGOttawa, Canada
Contact Email: •••••@•••••
Contact
-
The University of Texas - MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
-
University of Cincinnati Vontz Center for Molecular Studies
RECRUITINGCincinnati, Ohio, 45219, United States
Contact
-
University of Colorado Hospital - Anschutz Cancer Pavilion
NOT_YET_RECRUITINGAurora, Colorado, 80045, United States
Contact
Contact Email: •••••@•••••
-
Wenzhou Medical University - The First Affiliated Hospital
RECRUITINGWenzhou, Zhejiang, 325000, China
Contact
-
West China Hospital, Sichuan University
NOT_YET_RECRUITINGChengdu, China
Contact Email: •••••@•••••
Contact
-
Yale School of Medicine - Yale Cancer Center - Smilow Cancer Hospital Care Centers - North Haven
RECRUITINGNorth Haven, Connecticut, 06473-2142, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.